# Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

> **NCT00694122** · PHASE3 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 27 (actual)

## Conditions studied

- Type 1 Diabetes
- Dawn Phenomenon

## Interventions

- **DRUG:** Lantus (glargine)

## Key facts

- **NCT ID:** NCT00694122
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694122, "Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00694122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*